1-7 of 7
Yufeng Li
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer

Logan D. Stone, Benjamin B. Kasten, Shilpa Rao, Manuel. L. Gonzalez, Todd M. Stevens, Diana Lin, William Carroll, Benjamin Greene, Lindsay S. Moore, Andrew Fuson, Sherin James, Yolanda E. Hartman, Susan McCammon, Bharat Panuganti, Lisle M. Nabell, Yufeng Li, Mei Li, Luke Bailey, Eben L. Rosenthal, Harishanker Jeyarajan, Carissa M. Thomas, Jason M. Warram
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (18): 4016–4028.
https://doi.org/10.1158/1078-0432.CCR-24-0940
Published: 13 September 2024
View article titled, Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Open the PDF for Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer in another window
Includes: Multimedia, Supplementary data
Journal Articles

18F-FMISO PET Imaging Identifies Hypoxia and Immunosuppressive Tumor Microenvironments and Guides Targeted Evofosfamide Therapy in Tumors Refractory to PD-1 and CTLA-4 Inhibition

Kirsten M. Reeves, Patrick N. Song, Allyson Angermeier, Deborah Della Manna, Yufeng Li, Jianbo Wang, Eddy S. Yang, Anna G. Sorace, Benjamin M. Larimer
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (2): 327–337.
https://doi.org/10.1158/1078-0432.CCR-21-2394
Published: 15 January 2022
View article titled, <sup>18</sup>F-FMISO PET Imaging Identifies Hypoxia and Immunosuppressive Tumor Microenvironments and Guides Targeted Evofosfamide Therapy in Tumors Refractory to PD-1 and CTLA-4 Inhibition
Open the PDF for <sup>18</sup>F-FMISO PET Imaging Identifies Hypoxia and Immunosuppressive Tumor Microenvironments and Guides Targeted Evofosfamide Therapy in Tumors Refractory to PD-1 and CTLA-4 Inhibition in another window
Includes: Supplementary data
Journal Articles

TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer

Andres Forero-Torres, Katherine E. Varley, Vandana G. Abramson, Yufeng Li, Christos Vaklavas, Nancy U. Lin, Minetta C. Liu, Hope S. Rugo, Rita Nanda, Anna M. Storniolo, Tiffany A. Traina, Sujata Patil, Catherine H. Van Poznak, Julie R. Nangia, William J. Irvin, Jr, Helen Krontiras, Jennifer F. De Los Santos, Paul Haluska, William Grizzle, Richard M. Myers, Antonio C. Wolff
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (12): 2722–2729.
https://doi.org/10.1158/1078-0432.CCR-14-2780
Published: 14 June 2015
View article titled, TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer
Open the PDF for TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019

Costanza Paoletti, Yufeng Li, Maria C. Muñiz, Kelley M. Kidwell, Kimberly Aung, Dafydd G. Thomas, Martha E. Brown, Vandana G. Abramson, William J. Irvin, Jr, Nancy U. Lin, Minetta C. Liu, Rita Nanda, Julie R. Nangia, Anna M. Storniolo, Tiffany A. Traina, Christos Vaklavas, Catherine H. Van Poznak, Antonio C. Wolff, Andres Forero-Torres, Daniel F. Hayes
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (12): 2771–2779.
https://doi.org/10.1158/1078-0432.CCR-14-2781
Published: 14 June 2015
View article titled, Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019
Open the PDF for Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019 in another window
Includes: Supplementary data
Journal Articles

Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma

Jahan S. Khalili, Shujuan Liu, Tania G. Rodríguez-Cruz, Mayra Whittington, Seth Wardell, Chengwen Liu, Minying Zhang, Zachary A. Cooper, Dennie T. Frederick, Yufeng Li, Min Zhang, Richard W. Joseph, Chantale Bernatchez, Suhendan Ekmekcioglu, Elizabeth Grimm, Laszlo G. Radvanyi, Richard E. Davis, Michael A. Davies, Jennifer A. Wargo, Patrick Hwu, Gregory Lizée
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (19): 5329–5340.
https://doi.org/10.1158/1078-0432.CCR-12-1632
Published: 30 September 2012
View article titled, Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma
Open the PDF for Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma in another window
Includes: Supplementary data
Journal Articles

Detection and Characterization of a Novel Subset of CD8+CD57+ T Cells in Metastatic Melanoma with an Incompletely Differentiated Phenotype

Richard C. Wu, Shujuan Liu, Jessica A. Chacon, Sheng Wu, Yufeng Li, Pariya Sukhumalchandra, James L. Murray, Jeffrey J. Molldrem, Patrick Hwu, Hanspeter Pircher, Gregory Lizée, Laszlo G. Radvanyi
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (9): 2465–2477.
https://doi.org/10.1158/1078-0432.CCR-11-2034
Published: 30 April 2012
View article titled, Detection and Characterization of a Novel Subset of CD8<sup>+</sup>CD57<sup>+</sup> T Cells in Metastatic Melanoma with an Incompletely Differentiated Phenotype
Open the PDF for Detection and Characterization of a Novel Subset of CD8<sup>+</sup>CD57<sup>+</sup> T Cells in Metastatic Melanoma with an Incompletely Differentiated Phenotype in another window
Includes: Supplementary data
Journal Articles

Synthetic MicroRNA Designed to Target Glioma-Associated Antigen 1 Transcription Factor Inhibits Division and Induces Late Apoptosis in Pancreatic Tumor Cells

Naotake Tsuda, Satoshi Ishiyama, Yufeng Li, Constantin G. Ioannides, James L. Abbruzzese, David Z. Chang
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (21): 6557–6564.
https://doi.org/10.1158/1078-0432.CCR-06-0588
Published: 03 November 2006
View article titled, Synthetic MicroRNA Designed to Target Glioma-Associated Antigen 1 Transcription Factor Inhibits Division and Induces Late Apoptosis in Pancreatic Tumor Cells
Open the PDF for Synthetic MicroRNA Designed to Target Glioma-Associated Antigen 1 Transcription Factor Inhibits Division and Induces Late Apoptosis in Pancreatic Tumor Cells in another window
Includes: Supplementary data